{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lifileucel", "query": { "intervention": "Lifileucel" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lifileucel&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T16:14:32.927Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02360579", "title": "Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Lifileucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2015-09-24", "completion_date": "2024-10-24", "has_results": true, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 23, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02360579" }, { "nct_id": "NCT05607095", "title": "A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma", "Melanoma", "Metastatic Uveal Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Lifileucel (LN-144/LN-145)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-11-01", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 2, "location_summary": "Harrison, New York • New York, New York", "locations": [ { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05607095" }, { "nct_id": "NCT05727904", "title": "Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Melanoma", "Unresectable Melanoma", "Melanoma" ], "interventions": [ { "name": "Lifileucel plus Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab with Optional Crossover Period", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 670, "start_date": "2023-03-30", "completion_date": "2030-03-01", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05727904" }, { "nct_id": "NCT05176470", "title": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Melanoma", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Stage IV Melanoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lifileucel", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Richard Wu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2022-07-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176470" }, { "nct_id": "NCT05398640", "title": "Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Unresectable Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "OOS AMTAGVI", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 48, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 36 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05398640" }, { "nct_id": "NCT06743126", "title": "SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma, Cutaneous Malignant" ], "interventions": [ { "name": "IMA203", "type": "BIOLOGICAL" }, { "name": "nivolumab plus relatlimab", "type": "BIOLOGICAL" }, { "name": "lifileucel", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "paclitaxel plus carboplatin", "type": "DRUG" }, { "name": "Albumin-Bound Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-01-14", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06743126" }, { "nct_id": "NCT06940739", "title": "A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Melanoma", "Metastatic Melanoma", "Ocular Melanoma" ], "interventions": [ { "name": "IOV-3001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2025-03-11", "completion_date": "2032-07", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 3, "location_summary": "Denver, Colorado • Chapel Hill, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06940739" }, { "nct_id": "NCT07288203", "title": "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin Cancer)", "Unresectable Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Lifileucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 100, "start_date": "2025-11-28", "completion_date": "2033-12", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288203" }, { "nct_id": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Lifileucel", "type": "BIOLOGICAL" }, { "name": "LN-145", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab-relatlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2019-05-07", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03645928" }, { "nct_id": "NCT06566092", "title": "Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma", "Primary Central Nervous System Carcinoma", "Melanoma", "Rhabdomyosarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "LN-145/LN-144", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 40, "start_date": "2024-03-28", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-03T16:14:32.927Z", "location_count": 5, "location_summary": "Aurora, Colorado • St. Petersburg, Florida • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06566092" } ] }